Targazyme Inc., founded in San Diego, is a clinical-stage biopharmaceutical company focused on developing novel enzyme-based platform technologies and products. Their core mission is to create best-in-class cancer immunotherapies to significantly improve the survival and quality of life for late-stage cancer patients globally. Targazyme's innovative proprietary cell efficacy multiplier technology aims to enhance the delivery of immune cells to disease sites and amplify the patient's inherent immune response. Their market focus includes cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, and gene therapy.

Notable affiliated individuals include experienced biopharmaceutical executives and leading scientists in oncology and immunotherapy. Targazyme has garnered attention from prominent investors in the biotech sector, contributing to its growth and development. Key achievements include advancing their proprietary technologies through clinical stages, demonstrating potential curative effects in late-stage liquid and solid cancers. The overall impact of Targazyme lies in its potential to revolutionize cancer treatment and improve patient outcomes through cutting-edge immunotherapy solutions.